Stereotaxis (STXS) Non-Current Debt (2010 - 2021)

Stereotaxis' (STXS) quarterly Non-Current Debt came in at $243617.0 in Q1 2021, down 74.97% quarter-over-quarter from $973252.0 in Q4 2020.

Analysis

Stereotaxis (STXS) Non-Current Debt (2010 - 2021) Analysis & Trends

Stereotaxis (STXS) has reported Non-Current Debt for 9 consecutive years, with $243617.0 the latest figure, recorded in Q1 2021.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $243617.0 in Q1 2021; TTM through Mar 2021 was $243617.0, a N/A change from a year earlier, with the FY2020 full-year figure at $973252.0, changed N/A from the prior year.
Non-Current Debt was $243617.0 for Q1 2021 at Stereotaxis, down from $973252.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $1.7 million in Q3 2020 and troughed at $243617.0 in Q1 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Abbott Laboratories	179.79 Bn	174.18 Bn	7.27 Bn	29.60 Bn
2	Intuitive Surgical	127.69 Bn	122.47 Bn	1.96 Bn	-
3	Medtronic	117.23 Bn	108.41 Bn	6.34 Bn	25.62 Bn
4	Stryker	103.55 Bn	100.07 Bn	4.50 Bn	14.19 Bn
5	Boston Scientific	63.24 Bn	62.70 Bn	3.85 Bn	10.92 Bn
6	Edwards Lifesciences	49.97 Bn	45.72 Bn	1.35 Bn	598.70 Mn
7	Alcon	32.83 Bn	31.37 Bn	1.68 Bn	-1.00 Mn
8	Dexcom	32.30 Bn	30.35 Bn	830.00 Mn	-
9	Steris	20.73 Bn	20.25 Bn	684.20 Mn	1.65 Bn
10	Stereotaxis	129.55 Mn	114.93 Mn	3.79 Mn	-

Historic Data

Download Data